You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Gastroenterology

Importance of Assessing Multiple Disease Domains in EoE

Prof. Arjan Bredenoord and Dr. Evan Dellon emphasize the need to assess multiple disease domains to get the complete picture of patients’ EoE.
Arjan Bredenoord
Evan Dellon
MD, PhD
Arjan Bredenoord +1 more

Learning objectives

  • Understand the importance of assessing symptoms, endoscopy, and histology when evaluating disease status in patients with EoE
  • Recognize the impact of different disease outcomes on patient burden

Description

Global experts Arjan Bredenoord, MD, PhD, and Evan Dellon, MD, emphasize the need to assess multiple disease domains to get the complete picture of a patient's EoE.

Tags
disease progressionsymptomsendoscopyhistologymultiple disease dimensions
MAT-GLB-2102863 v2.0 07/2021

About these experts

Gastroenterology
MD, PhD

Arjan Bredenoord

Professor of Neurogastroenterology & Motility | University of Amsterdam, Netherlands; Consultant Gastroenterologist | Amsterdam University Medical Centers

Gastroenterology
MD, MPH

Evan Dellon

Professor of Medicine and Adjunct Professor of Epidemiology | University of North Carolina School of Medicine, Chapel Hill, United States

Related resources

Complex EoE Pathophysiology Beyond Esophageal Eosinophilia
Gastroenterology
expert video

Complex EoE Pathophysiology Beyond Esophageal Eosinophilia

Importance of Assessing Multiple Disease Domains in EoE
Gastroenterology
expert video

Importance of Assessing Multiple Disease Domains in EoE

EoE Burden and Pathophysiology of Type 2 Inflammation
Gastroenterology
videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region